Literature DB >> 9281871

Dog bites in Bosnia.

A Croft1, R Archer.   

Abstract

BACKGROUND: Rabies is a zoonosis that remains endemic in most parts of the world. Primary care physicians are in the first line of defence against the disease. An increasing number of British practitioners and medical students are being exposed to the dangers of rabies through humanitarian work on overseas attachments. Rabies is enzootic throughout Bosnia-Herzegovina and presents a hazard to the multinational troops currently deployed there. AIM: To describe the British Army's experience of animal bites and rabies prevention in Bosnia during the first six months of its current peace enforcement mission, and to make general recommendations on the good management of any rabies hazard at primary care level and under field conditions.
METHODS: Routine data from the Army's epidemiological database (ARRC 97) were reviewed, and theatre issues of rabies vaccine and immune globulin were used as a proxy measure for administered post-exposure prophylaxis.
RESULTS: A total of 62 animal bites were reported in British troops between December 1995 and May 1996, of which 28 were unprovoked bites and resulted in the administration of a course of rabies vaccine. Ten of these were severe bites and rabies immune globulin (RIG) was administered in addition. The total cost of rabies post-exposure prophylaxis was US$6914.00.
CONCLUSION: The prevention of rabies has major human and resource implications, and primary care staff involved in rabies post-exposure management need to be well supported in their clinical decision-making. Rabies protocols should be clear and unambiguous. The effective medical surveillance of military or humanitarian missions in rabies-enzootic areas must include the prompt reporting of animal bites. The predeployment training of medical teams should include an up-to-date assessment of the local rabies threat.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9281871      PMCID: PMC1313054     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  22 in total

1.  Sports injuries in British troops deployed on Operation Resolute (Bosnia)

Authors:  M S Adams; A M Croft
Journal:  J R Army Med Corps       Date:  1997-02       Impact factor: 1.285

2.  Guillain-Barré syndrome and human diploid cell rabies vaccine.

Authors:  T Knittel; G Ramadori; W J Mayet; H Löhr; K H Meyer zum Büschenfelde
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

3.  Adverse effects of equine rabies immune gobulin.

Authors:  H Wilde; P Chomchey; S Prakongsri; P Puyaratabandhu; S Chutivongse
Journal:  Vaccine       Date:  1989-02       Impact factor: 3.641

4.  Atypical rabies in dogs in Ethiopia.

Authors:  M Fekadu
Journal:  Ethiop Med J       Date:  1972-07

5.  Neuroparalytic illness and human diploid cell rabies vaccine.

Authors:  K W Bernard; P W Smith; F J Kader; M J Moran
Journal:  JAMA       Date:  1982-12-17       Impact factor: 56.272

6.  Guillain-Barré syndrome after vaccination with human diploid cell rabies vaccine.

Authors:  E Bøe; H Nyland
Journal:  Scand J Infect Dis       Date:  1980

7.  Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine.

Authors:  D W Dreesen; K W Bernard; R A Parker; A J Deutsch; J Brown
Journal:  Vaccine       Date:  1986-03       Impact factor: 3.641

8.  Clinical experience with a human diploid cell rabies vaccine.

Authors:  L J Anderson; W G Winkler; B Hafkin; R A Keenlyside; L J D'Angelo; M W Deitch
Journal:  JAMA       Date:  1980 Aug 22-29       Impact factor: 56.272

9.  Postexposure trial of a human diploid cell strain rabies vaccine.

Authors:  L J Anderson; R K Sikes; C W Langkop; J M Mann; J S Smith; W G Winkler; M W Deitch
Journal:  J Infect Dis       Date:  1980-08       Impact factor: 5.226

10.  [Meningoradiculitis after injection of an antirabies vaccine. A vaccine from human diploid cell culture].

Authors:  A Moulignier; A Richer; C Fritzell; D Foulon; P Khoubesserian; J de Recondo
Journal:  Presse Med       Date:  1991-06-22       Impact factor: 1.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.